...
首页> 外文期刊>Mutation Research: International Journal on Mutagenesis, Chromosome Breakage and Related Subjects >Tissue-specific induction of mutations by acute oral administration of N-methyl-N'-nitro-N-nitrosoguanidine and beta-propiolactone to the Muta Mouse: preliminary data on stomach, liver and bone marrow.
【24h】

Tissue-specific induction of mutations by acute oral administration of N-methyl-N'-nitro-N-nitrosoguanidine and beta-propiolactone to the Muta Mouse: preliminary data on stomach, liver and bone marrow.

机译:向Muta小鼠急性口服N-甲基-N'-硝基-N-亚硝基胍和β-丙内酯对组织的突变诱导突变:关于胃,肝和骨髓的初步数据。

获取原文
获取原文并翻译 | 示例
           

摘要

We used the positive selection Muta Mouse model to detect organ-specific activity of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and beta-propiolactone (BPL), two highly reactive alkylating agents known to induce genetic damage and tumors in rodent stomach when administered orally. Seven days after a single oral administration of MNNG (100 mg/kg) or BPL (150 mg/kg), the mutation frequency in the Muta Mouse stomach increased significantly by 6.4-fold and 8.8-fold, respectively. A slight (1.8-fold) but significant increase in mutation frequency was also observed in the livers of BPL-treated mice, but not in the livers of MNNG-treated mice or the bone marrow of MNNG- and BPL-treated animals. These data indicate that the Muta Mouse model can be used to predict the gastric specificity of genotoxic carcinogens.
机译:我们使用正选择Muta小鼠模型来检测N-甲基-N'-硝基-N-亚硝基胍(MNNG)和β-丙内酯(BPL)的器官特异性活性,这两种高反应性烷基化剂是已知可引起遗传损伤和肿瘤的口服时在啮齿动物的胃中。单次口服MNNG(100 mg / kg)或BPL(150 mg / kg)七天后,Muta小鼠胃中的突变频率分别显着增加了6.4倍和8.8倍。在BPL处理的小鼠的肝脏中也观察到突变频率的轻微增加(1.8倍),但显着增加,但在MNNG处理的小鼠的肝脏或MNNG和BPL处理的动物的骨髓中没有观察到。这些数据表明Muta小鼠模型可用于预测遗传毒性致癌物的胃特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号